Academic Heart

[Academic Heart @AcademicHeart]

AURORA Trial

Flurpiridaz F-18 PET vs Tc-99 SPECT for CAD

In @JACCJournals
👀https://t.co/3vmqY0E40i

F-18 assoc with:
🤎⬆️ sensitivity
🧡Equal specificity
💛⬆️ image quality
💚⬆️ diagnostic certainty
💙⬇️radiation exposure

F-18 half-life = 110 min permits exercise stress

[Academic Heart @AcademicHeart]

Image of the week
From @Bertolin_Car
AV Papillary Fibroelastoma

[Academic Heart @AcademicHeart]

CUFF(SZ) Trial

Effect of Cuff Size on the Accuracy of BP Readings

From @JAMA_current @JAMAInternalMed

👀https://t.co/v7PBAN4e6T

Wrong cuff size can greatly affect accuracy of BP measurements.

[Academic Heart @AcademicHeart]

SURMOUNT-3 Trial

Tirzepatide v placebo after lifestyle intervention

In @NatureMedicine
👀https://t.co/KEgVToKEef

All lost 5% weight with lifestyle bf randomization

Then:
💚Tirz = 18.4% weight loss
🤎Placebo = 3.3% weight gain

[Academic Heart @AcademicHeart]

Adherence to CPAP Treatment and Risk of Recurrent CV Events: Meta-Analysis 💤

From @JAMA_current
👀https://t.co/eoMMWALdvr

Intention-to-treat CPAP does not reduce CV events.

4+ hours of CPAP adherence does reduce CV events by 30% (HR 0.69).

[Academic Heart @AcademicHeart]

ADAPTABLE: Enteric-Coated ASA v Uncoated ASA

Secondary Analysis
From @JAMACardio
👀https://t.co/cTGgnuOcR7

Enteric-coated:
💛No diff ischemic events
💙No diff bleeding events

The only time to favor one over the other is ACS: use uncoated for rapid absorption.

[Academic Heart @AcademicHeart]

@MHBeasleyMD @docbhardwaj @priyaumapathi @FudimMarat @mkonstam @JJheart_doc @HFSA @MHBeasleyMD Pls send us what we missed!

[Academic Heart @AcademicHeart]

🔥CV Conference Calendar🔥
https://t.co/C9ax0iVSfc

[Academic Heart @AcademicHeart]

TARGET-HTN Trial

Phase 2 trial of Lorundrostat versus placebo for HTN

From @JAMA_current

💜LDS is aldosterone synthase inhibitor
💙LDS reduced SBP up to 14 mmHg
💚LDS caused rare hyperK

https://t.co/56dXpbTKsb👀

[Academic Heart @AcademicHeart]

FDA advisory committee voted 9 to 3 in favor of patisiran benefit-risk profile for ATTR-CM

Patisiran
🤎FDA-approved for hereditary ATTR w neuropathy
🧡Under eval in APOLLO-B P3 trial for ATTR-CM
💛An IV RNAi that inhibits TTR synthesis

👀https://t.co/Sr5wRz2Fcb

[Academic Heart @AcademicHeart]

DOAC SCORE

New tool to predict bleeding risk among AFib patients on DOACs.

In @CircAHA
👀https://t.co/bu21jIFy3h

🤎10 variables
🧡Performed better than HAS-BLED
💛Awaiting online calculator

#CardioTwitter #ACCFIT

[Academic Heart @AcademicHeart]

Muvalaplin, an oral small molecule inhibitor of Lp(a) formation: Phase 1 trial

In @JAMA_current
👀https://t.co/1pY5o2lrj4

💚Reduced Lp(a) up to 60%
💙No adverse effects

Lp(a) is 🔥 target to ⬇️ ASCVD and AS based on observational data.

No Lp(a) therapy yet FDA-approved.

[Academic Heart @AcademicHeart]

MULTISTARS AMI Trial

Timing of complete revasc w multivessel PCI for AMI

From #esccongress2023
In @NEJM

👀https://t.co/FFfl9JuGlL

Complete revasc at time of culprit revasc was better than staging non-culprit revasc in 19-45 day window

[Academic Heart @AcademicHeart]

Outcomes of Repeat TAVR with Balloon Expandable Valves

In @TheLancet

Largest registry study shows redo-TAVR is safe and effective with 1-yr follow up.

Redo compared to index TAVR:
💛No diff 1-yr death
🧡No diff rehosp
🤎1-year MG 15 v 12 mmHg

👀https://t.co/gkVT5WeXeJ

[Academic Heart @AcademicHeart]

LODESTAR Trial
Rosuvastatin v atorvastatin 🥊

From #esccongress2023
No simultaneous publication

Rosuvastatin =
❤️Lower LDL
🧡No diff death
💛No diff AMI
💚More diabetes
💙More cataracts

From ACC:

[Academic Heart @AcademicHeart]

ECLS-SHOCK Trial

From #esccongress2023
In @NEJM

👀https://t.co/NDO1mGBOCP

VA-ECMO in AMI-related shock:
💛No diff mortality
🧡Increased bleeding

Same as:
💙IABP SHOCK II Trial (IABP)
💚IMPRESS Trial (Impella)

[Academic Heart @AcademicHeart]

Image of the week
Quadricuspid Aortic Valve
#WhyCMR

[Academic Heart @AcademicHeart]

🌟Cardiology Conference Calendar🌟

ESC Congress is over! What's up next?

👀https://t.co/KndsFmgdX4

[Academic Heart @AcademicHeart]

Image of the week
https://t.co/KndsFmgLMC
👀LAA thrombus

[Academic Heart @AcademicHeart]

Peripheral Admin of Norepi

Prospective observational study

From @accpchest
👀https://t.co/Ayuiee7dV0

635 patients:
💙20% received for 24+ hrs
💚51% avoided central line
💛5% had extravasation events

Peripheral NE for short term is safe as bridge to CVC or to avoid CVC